journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/28623181/allele-level-hla-matching-for-umbilical-cord-blood-transplantation-for-non-malignant-diseases-in-children-a-retrospective-analysis
#1
Mary Eapen, Tao Wang, Paul A Veys, Jaap J Boelens, Andrew St Martin, Stephen Spellman, Carmem Sales Bonfim, Colleen Brady, Andrew J Cant, Jean-Hugues Dalle, Stella M Davies, John Freeman, Katherine C Hsu, Katharina Fleischhauer, Chantal Kenzey, Joanne Kurtzberg, Gerard Michel, Paul J Orchard, Annalisa Paviglianiti, Vanderson Rocha, Michael R Veneris, Fernanda Volt, Robert Wynn, Stephanie J Lee, Mary M Horowitz, Eliane Gluckman, Annalisa Ruggeri
BACKGROUND: The standard for selecting unrelated umbilical cord blood units for transplantation for non-malignant diseases relies on antigen-level (lower resolution) HLA typing for HLA-A and HLA-B, and allele-level for HLA-DRB1. We aimed to study the effects of allele-level matching at a higher resolution-HLA-A, HLA-B, HLA-C, and HLA-DRB1, which is the standard used for adult unrelated volunteer donor transplantation for non-malignant diseases-for umbilical cord blood transplantation...
June 13, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28602585/janus-kinase-2-inhibitor-fedratinib-in-patients-with-myelofibrosis-previously-treated-with-ruxolitinib-jakarta-2-a-single-arm-open-label-non-randomised-phase-2-multicentre-study
#2
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Ramon V Tiu, Pierre Zachee, Eric Jourdan, Elliott Winton, Richard T Silver, Harry C Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A Mesa
BACKGROUND: Myelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including fatigue, weight loss, and bone pain. Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of patients. The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib. 58-71% of patients treated with ruxolitinib in clinical trials so far have not achieved the primary endpoint of 35% or more reduction in spleen volume from baseline assessed by MRI or CT...
June 8, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28602584/how-to-define-treatment-failure-for-jak-inhibitors
#3
Hans Michael Kvasnicka
No abstract text is available yet for this article.
June 8, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28566210/the-destiny-of-chronic-myeloid-leukeamia
#4
Elisabetta Abruzzese
No abstract text is available yet for this article.
May 26, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28566209/de-escalation-of-tyrosine-kinase-inhibitor-dose-in-patients-with-chronic-myeloid-leukaemia-with-stable-major-molecular-response-destiny-an-interim-analysis-of-a-non-randomised-phase-2-trial
#5
Richard E Clark, Fotios Polydoros, Jane F Apperley, Dragana Milojkovic, Christopher Pocock, Graeme Smith, Jenny L Byrne, Hugues de Lavallade, Stephen G O'Brien, Tony Coffey, Letizia Foroni, Mhairi Copland
BACKGROUND: Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some patients with chronic myeloid leukaemia with deep molecular responses; however, patients with stable major molecular response (MMR), but not MR4, have not been studied, nor has the effect of treatment de-escalation rather than outright cessation. We aimed to examine the effects of treatment de-escalation as a prelude to complete cessation, not only in patients with MR4 or greater, but also in those with MMR but not MR4...
May 26, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28411122/the-lure-and-pitfalls-of-administrative-health-registers
#6
Søren Paaske Johnsen
No abstract text is available yet for this article.
April 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28389344/emergency-transfusion-of-patients-with-unknown-blood-type-with-blood-group-o-rhesus-d-positive-red-blood-cell-concentrates-a-prospective-single-centre-observational-study
#7
Kathleen Selleng, Gregor Jenichen, Kathrin Denker, Sixten Selleng, Bernd Müllejans, Andreas Greinacher
BACKGROUND: Emergency patients with unknown blood type usually receive O Rhesus D negative (RhD-) red blood cell concentrates until their blood group is determined to prevent RhD+ related adverse transfusion reactions. As 85% of individuals are RhD+, this consumption of O RhD- red blood cell concentrates contributes to shortages of O RhD- red blood cell concentrates, sometimes forcing transfusion of known RhD- patients with RhD+ red blood cell concentrates. Here we report the outcome of this transfusion policy transfusing all emergency patients with unknown blood type with O RhD+ red blood cell concentrates...
April 4, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583289/long-term-outcomes-after-standard-graft-versus-host-disease-prophylaxis-with-or-without-anti-human-t-lymphocyte-immunoglobulin-in-haemopoietic-cell-transplantation-from-matched-unrelated-donors-final-results-of-a-randomised-controlled-trial
#8
Jürgen Finke, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Liisa Volin, Dominik Heim, Hartmut Bertz, Olga Grishina, Gerard Socie
BACKGROUND: Previously, we demonstrated that the addition of anti-human-T-lymphocyte immunoglobulin (ATLG) to standard ciclosporin and methotrexate prophylaxis reduced graft-versus-host disease (GvHD) in adult patients treated with allogeneic haemopoietic cell transplantation from matched unrelated donors without negatively affecting relapse and survival. Since reports on long-term results from randomised trials testing anti-thymocyte globulin are scarce, we performed an extended follow-up of the trial...
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583288/correction-to-lancet-haematol-2017-4-e165-75
#9
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583287/correction-to-lancet-haematol-2017-4-e258-71
#10
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583286/evaluation-of-direct-oral-anticoagulants-in-superficial-vein-thrombosis-authors-reply
#11
LETTER
Jan Beyer-Westendorf, Sebastian M Schellong, Horst Gerlach, Eberhard Rabe, Jeffrey I Weitz, Katja Jersemann, Kurtulus Sahin, Rupert Bauersachs
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583285/evaluation-of-direct-oral-anticoagulants-in-superficial-vein-thrombosis
#12
LETTER
Paul Frappé, Laurent Bertoletti, Claire Le Hello, Hervé Décousus, Silvy Laporte
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583284/unrelated-donor-haemopoietic-stem-cell-transplantation-atg-or-not
#13
Frédéric Baron
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583283/subcutaneous-rituximab-a-meaningful-advance-in-care
#14
Sarit Assouline
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28583282/putting-a-stop-to-exsanguination
#15
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28522110/high-dose-gemcitabine-busulfan-and-melphalan-for-autologous-stem-cell-transplant-in-patients-with-relapsed-or-refractory-myeloma-a-phase-2-trial-and-matched-pair-comparison-with-melphalan
#16
Yago Nieto, Benigno C Valdez, Sai R Pingali, Roland Bassett, Ruby Delgado, John Nguyen, Nina Shah, Uday Popat, Roy B Jones, Borje S Andersson, Alison Gulbis, Sairah Ahmed, Qaiser Bashir, Simrit Parmar, Krina Patel, Alan Myers, Gabriela Rondon, Robert Z Orlowski, Richard Champlin, Muzaffar Qazilbash
BACKGROUND: High-dose melphalan is of little benefit as a regimen for patients with relapsed or refractory myeloma undergoing an autologous stem-cell transplant (ASCT). The poor performance of single-agent melphalan in this setting prompted us to study a new high-dose combination of infused gemcitabine, busulfan, and melphalan. METHODS: We did a phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). We enrolled patients with primary refractory or relapsed myeloma who had received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a salvage ASCT...
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28522109/gemcitabine-busulfan-and-melphalan-conditioning-for-autologous-stem-cell-transplants-in-multiple-myeloma
#17
Gösta Gahrton
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28476440/efficacy-and-safety-of-subcutaneous-rituximab-versus-intravenous-rituximab-for-first-line-treatment-of-follicular-lymphoma-sabrina-a-randomised-open-label-phase-3-trial
#18
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett, David MacDonald
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries...
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28457981/coagulation-factor-concentrates-and-point-of-care-coagulation-monitoring-both-might-be-essential-for-optimal-treatment-of-trauma-induced-coagulopathy
#19
Oliver Grottke, Rolf Rossaint
No abstract text is available yet for this article.
June 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28457980/reversal-of-trauma-induced-coagulopathy-using-first-line-coagulation-factor-concentrates-or-fresh-frozen-plasma-retic-a-single-centre-parallel-group-open-label-randomised-trial
#20
Petra Innerhofer, Dietmar Fries, Markus Mittermayr, Nicole Innerhofer, Daniel von Langen, Tobias Hell, Gottfried Gruber, Stefan Schmid, Barbara Friesenecker, Ingo H Lorenz, Mathias Ströhle, Verena Rastner, Susanne Trübsbach, Helmut Raab, Benedikt Treml, Dieter Wally, Benjamin Treichl, Agnes Mayr, Christof Kranewitter, Elgar Oswald
BACKGROUND: Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure. METHODS: This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria)...
June 2017: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"